GEM 91 antisense agent complementary to the RNA packaging site and gag initiation site of HIV-1 data

The Worcester, Mass., company presented in vitro data showing that HIV failed to develop resistance to the drug, which is in Phase Ib/II trials. The anti-viral activity of the agent was effective agai...